21 results
8-K
EX-99.1
MCRB
Seres Therapeutics Inc
9 Jan 24
Regulation FD Disclosure
7:05am
million in annual cash savings* Workforce - Reduced by 41% or ~160 positions across the organization R&D - Significantly scaled back all non-partnered … anticipates incurring a one-time charge of $5.0-$5.5 million in the fourth quarter of 2023, primarily related to the workforce reduction. | Seres
8-K
EX-99.1
1yy21a1ci9ahjdm61u
2 Nov 23
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
7:05am
PRE 14A
iicpjnvnnoakwaj
14 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.1
o91ee m71f06
2 May 19
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
7:03am
8-K
EX-99.1
r56elhvweif3ok4x8
6 Mar 19
Results of Operations and Financial Condition
7:00am